152 related articles for article (PubMed ID: 36127509)
21. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma.
Sun Z; Liu M
Cytotherapy; 2022 Sep; 24(9):940-953. PubMed ID: 35568624
[TBL] [Abstract][Full Text] [Related]
23. CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study.
Benoit A; B Boies MH; Déry N; M Garcia L; Simard M; Poirier M; Delage R; Lortal Canguilhem B; Doyle C; Larouche JF; Couture F; Lemieux C
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):203-210. PubMed ID: 36646606
[TBL] [Abstract][Full Text] [Related]
24. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
26. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
[TBL] [Abstract][Full Text] [Related]
27. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC; Gunther JR; Dabaja BS; Strati P; Fang P; Hawkins MC; Adkins S; Westin J; Ahmed S; Fayad L; Lee HJ; Nair R; Steiner RE; Iyer SP; Rodriguez MA; Wang M; Flowers C; Neelapu SS; Nastoupil LJ
Blood Adv; 2020 Jul; 4(13):2871-2883. PubMed ID: 32589728
[TBL] [Abstract][Full Text] [Related]
28. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
29. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data.
Messori A; Chiumente M; Mengato D
Clin Ther; 2022 Dec; 44(12):1626-1632. PubMed ID: 36503735
[TBL] [Abstract][Full Text] [Related]
33. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes.
Figura NB; Sim AJ; Jain MD; Chavez JC; Robinson TJ
Expert Rev Hematol; 2022 Dec; 15(12):1023-1030. PubMed ID: 36369950
[TBL] [Abstract][Full Text] [Related]
34. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
35. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
36. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
Zurko JC; Fenske TS; Johnson BD; Bucklan D; Szabo A; Xu H; Chaney K; Hamadani M; Hari P; Shah NN
Am J Hematol; 2022 Dec; 97(12):1580-1588. PubMed ID: 36068950
[TBL] [Abstract][Full Text] [Related]
38. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
Westin J; Sehn LH
Blood; 2022 May; 139(18):2737-2746. PubMed ID: 35240677
[TBL] [Abstract][Full Text] [Related]
39. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
40. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Gauthier J; Gazeau N; Hirayama AV; Hill JA; Wu V; Cearley A; Perkins P; Kirk A; Shadman M; Chow VA; Gopal AK; Hodges Dwinal A; Williamson S; Myers J; Chen A; Nagle S; Hayes-Lattin B; Schachter L; Maloney DG; Turtle CJ; Sorror ML; Maziarz RT
Blood; 2022 Jun; 139(26):3722-3731. PubMed ID: 35439295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]